Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL573175 | 1.00 | DCTPP1 (0.40) | DCTPP1MAPTMAPK1HCAR3CYP1A2 | |
| SCHEMBL573174 | 1.00 | DCTPP1 (0.40) | DCTPP1MAPTMAPK1HCAR3CYP1A2 | |
| SCHEMBL15192170 | 0.83 | DCTPP1 (0.40) | DCTPP1MAPTMAPK1HCAR3CYP1A2 | |
| SCHEMBL571705 | 0.83 | DCTPP1 (0.40) | DCTPP1MAPTMAPK1HCAR3CYP1A2 | |
| SCHEMBL572364 | 0.83 | DCTPP1 (0.44) | DCTPP1MAPTMAPK1HCAR3CYP1A2 | |
| SCHEMBL572590 | 0.80 | CNR1 (0.42) | DCTPP1MAPTMAPK1HTTALDH1A1 | |
| SCHEMBL572591 | 0.80 | CNR1 (0.42) | DCTPP1MAPTMAPK1HTTALDH1A1 | |
| SCHEMBL573184 | 0.80 | HCAR3 (0.43) | DCTPP1MAPTMAPK1HCAR3CYP1A2 | |
| SCHEMBL15192877 | 0.79 | SETD7 (0.37) | DCTPP1MAPTMAPK1HTTALDH1A1 | |
| SCHEMBL572206 | 0.79 | SETD7 (0.37) | DCTPP1MAPTMAPK1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC (US) | 2016-02-18 | — | — | US | disclosed |
| US-9115127-B2 | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2611784-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | Amgen, Inc (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012018668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | DCTPP1 1233/4885MAPT 3852/4885MAPK1 156/4885 |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | DCTPP1 1233/4885MAPT 3852/4885MAPK1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.